Trials like CREST and Potomac show a consistent but modest event-free survival benefit when adding a PD-1 inhibitor to BCG for high-risk non-muscle-invasive bladder cancer. However, this comes with significant toxicity and no current overall survival benefit, creating a complex risk-benefit discussion for patients.

The Sac o six nineteen trial showed compelling results adding BCG to a chemo-immunotherapy backbone. However, the standard of care has already shifted to a newer combination (enfortumab vedotin and pembrolizumab), making it difficult to translate the study's findings into current practice and complicating the design of future trials.

Clinicians must weigh the immediate benefits of adding a PD-1 inhibitor for non-muscle-invasive bladder cancer against the potential loss of efficacy for crucial systemic therapies like EV-pembro if the disease later becomes metastatic. This introduces a new layer of long-term treatment strategy from the first diagnosis.

In the Keynote 522 trial for early-stage TNBC, adding pembrolizumab to chemotherapy resulted in only a modest improvement in pathological complete response (pCR). Surprisingly, this small initial gain translated into much more robust and significant long-term improvements in event-free and overall survival.

While adding PD-1 inhibitors to standard BCG therapy in high-risk non-muscle-invasive bladder cancer improves event-free survival, it also introduces significant Grade 3 toxicity (around 24%) without mature overall survival data, making its risk-benefit profile questionable.

When debating immunotherapy risks, clinicians separate manageable side effects from truly life-altering events. Hypothyroidism requiring a daily pill is deemed acceptable, whereas toxicities like diabetes or myocarditis (each ~1% risk) are viewed as major concerns that heavily weigh on the risk-benefit scale for early-stage disease.

Despite widespread use in oncology, immunotherapy has limited efficacy in extrapulmonary NEC. Real-world data for combination CTLA-4 and PD-1 inhibitors show response rates around 15%, with sustained responses in less than 10% of patients. This highlights the urgent need for novel therapeutic approaches beyond checkpoint inhibition.

Using a PD-1 inhibitor upfront with BCG for non-muscle-invasive bladder cancer is not an isolated decision. It creates a significant strategic challenge: this early exposure may compromise the efficacy of crucial systemic immunotherapies, like EV-Pembro, if the disease later progresses to a metastatic stage, forcing difficult long-term planning.

The CREST and Potomac trials showed adding immunotherapy to standard BCG treatment improves event-free survival by only ~5% at 24 months. This modest gain comes with a five-fold increase in significant adverse events, creating a crucial risk-reward discussion for patients.